• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Alder Biopharmaceuticals

edit

Alder has worked to make a significant contribution to the field of antibody therapeutics using two proprietary platform technologies that accelerate antibody discovery and development. These technologies provide the foundation for addressing a range of unmet medical needs, and have allowed them to accelerate their first product into the clinic for the treatment of cancer and rheumatoid arthritis.

Recent Milestones

edit

• 
  Alder Biopharmaceuticals received $38M in Series D funding. (4/19/12)
  Posted 4/19/12 at 5:20am via prnewswire.com
• 
  Alder Biopharmaceuticals received $15M in Venture Round funding. (6/20/11)
  Posted 6/20/11 at 7:49pm via fiercebiotech.com
• 
  Alder Biopharmaceuticals added Randall C. Schatzman as President & CEO.
  Posted 6/20/11 at 7:48pm
• 
  Alder Biopharmaceuticals added Larry Benedict as Vice President, Finance.
  Posted 6/20/11 at 7:48pm

Videos

Screenshots

edit

Sources

1. Alder lands $15M milestone from blockbuster BMS antibody deal (fiercebiotech.com) [edit]
2. Alder BioPharmaceuticals Inc. Closes $38 Million Series D Financing to Accelerate Clinical Development of its Pipeline of Antibody Therapeutics (prnewswire.com) [edit]